Terns Pharmaceuticals, Inc. Long Term Tax Liability (Deferred)

Long Term Tax Liability (Deferred) of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long Term Tax Liability (Deferred) growth rates and interactive chart.


Highlights and Quick Summary

  • Long Term Tax Liability (Deferred) for the quarter ending December 31, 2021 was $787 Thousand (a 4818.75% increase compared to previous quarter)
  • Year-over-year quarterly Long Term Tax Liability (Deferred) increased by 505.38%
  • Annual Long Term Tax Liability (Deferred) for 2021 was $787 Thousand (a 19.79% increase from previous year)
  • Annual Long Term Tax Liability (Deferred) for 2020 was $657 Thousand (a 90.43% increase from previous year)
  • Annual Long Term Tax Liability (Deferred) for 2019 was $345 Thousand (a 142.96% increase from previous year)
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long Term Tax Liability (Deferred) of Terns Pharmaceuticals, Inc.

Most recent Long Term Tax Liability (Deferred)of TERN including historical data for past 10 years.

Interactive Chart of Long Term Tax Liability (Deferred) of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Long Term Tax Liability (Deferred) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.79 $0.02 $0.79
2020 $0.66 $0.13 $0.66
2019 $0.35 $0.35
2018 $0.14

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.